We are a health economics, HTA, and market access consultancy serving the MENA and GCC region. We convert fragmented health data into decision-ready evidence — HTA dossiers, economic models, real-world evidence, and pricing strategies — that reflect how payers and HTA bodies in the region actually make reimbursement decisions.

Our name comes from the QALY — the Quality-Adjusted Life Year, the core measure health economists use to capture the value of a therapy in both length and quality of life. It reflects what we stand for: putting measurable patient value at the center of every access decision.

Two main groups. Pharmaceutical companies seeking market access, reimbursement, and evidence strategy for innovative therapies — and governmental health entities building HTA capacity, developing policy, and transforming their health systems toward value-based decision-making.

Our core delivery spans the GCC — Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, and Oman — extending across the wider MENA region.

Global evidence packages frequently fall short in local decision contexts because of the region’s unique regulatory, epidemiological, and budgetary conditions. We ground every model, dossier, and strategy in local data, national guidelines, and the actual expectations of regional payers — which is what determines whether a submission succeeds.